AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline - AbbVie

Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease Acquisition also allows AbbVie to utilize...Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute